Click here for Analysts' Upgrades, Downgrades.
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
price target lifted at Barclays to $41 from $36. We look for positive earnings revisions to drive the shares higher on improving license trends and margin leverage, Barclays said. Reiterate Overweight rating.
BJ's Wholesale Club
target, estimates boosted at Citi. BJ price target raised to $49 from $42 as margin improvement fuels 3Q10 EPS surprise, Citigroup said. 2011 and 2012 EPS estimates increased to $2.54 and $2.94, respectively. Hold rating.
( BUCY) price target boosted at Barclays to $92 from $80. CAT deal is testament to the strength of the global mining industry, Barclays said. Reiterate Overweight rating.
Catalyst Health Solutions
( CHSI) estimate boosted at Barclays to $2.39 from $2.20, 2010 held at $1.80. Change in estimate reflects anticipated adjustment to reported results post FutureScripts acquisition, Barclays said. Maintain Overweight rating.
( JOYG) price target higher at Barclays to $82 from $74. CAT-BUCY deal affirms mining up-cycle, but it also creates a stronger competitor, Barclays said. Maintain Overweight rating.
price target jumped at Citi to $60 from $50. Impressive quarter despite share count headwind, Citigroup said. Reiterate Buy rating.
price target raised at Credit Suisse. PETM price target increased to $42 from $41. In line 3Q10 results, solid outlook, Credit Suisse said. 2011 and 2012 EPS estimates lifted to $2.00 and $2.30, respectively. Maintain Outperform rating.
price target lifted at Citi by a dollar to $25 on market share recovery and profitable growth, Citigroup said. 2011 and 2012 EPS estimates raised to $1.78 and $2.03, respectively. Maintain Buy rating.
Teekay Offshore Partners
price target boosted at Citi to $31.50 from $26. Expect strong 4Q after 3Q maintenance season, Citigroup said. Maintain Buy rating.
price target higher at Citi to $2.75 from $2.50. Improving the subscriber mix with international LD plans, Citigroup said. Maintain Hold rating.
Updated at 10:11 a.m. with items below
target increased at Morgan Stanley to $16. Company is seeing better orders across the board. Overweight rating.
estimates boosted at Goldman through 2012. Company upped its guidance. Buy rating and $24 price target.
estimates, target raised at Goldman. Shares of CHS now seen reaching $9. Estimates also increased, given tight cost controls. Sell rating.
numbers boosted at Morgan Stanley. Shares of HNZ now seen reaching $52. Estimates also upped, given better exchange rates. Overweight rating.
numbers raised at UBS. Shares of LTD now seen reaching $37. Estimates also increased, as the company is generating sales and margin growth. Buy rating.
estimates lowered at UBS through 2012. Company is seeing a higher share count. Buy rating and $58 price target.
estimates, target increased at Goldman. PETM estimates were raised through 2012. Higher sales are driving better margins. Neutral rating and new $41 price target.
estimates upped at Goldman through 2012. Company should see better near-term sales. Neutral rating and $55 price target.
estimates upped at Morgan Stanley through 2012. Company boosted its forward guidance. Equal-weight rating.
target boosted at UBS to $91. Company should see a higher multiple. Buy rating.
This article was written by a staff member of TheStreet.